WO2017119455A1 - 自閉症スペクトラム障害の予防または治療剤 - Google Patents
自閉症スペクトラム障害の予防または治療剤 Download PDFInfo
- Publication number
- WO2017119455A1 WO2017119455A1 PCT/JP2017/000166 JP2017000166W WO2017119455A1 WO 2017119455 A1 WO2017119455 A1 WO 2017119455A1 JP 2017000166 W JP2017000166 W JP 2017000166W WO 2017119455 A1 WO2017119455 A1 WO 2017119455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethyl
- indeno
- dihydro
- oxazol
- acetamide
- Prior art date
Links
- FPSGQRJKKPVCHW-UHFFFAOYSA-N CC(NCCC1c2c3[o]c(CCc4ccccc4)nc3ccc2CC1)=O Chemical compound CC(NCCC1c2c3[o]c(CCc4ccccc4)nc3ccc2CC1)=O FPSGQRJKKPVCHW-UHFFFAOYSA-N 0.000 description 1
- YIMZWSKKOJHNCV-UHFFFAOYSA-N CC(NCCC1c2c3[o]c(CO)nc3ccc2CC1)=O Chemical compound CC(NCCC1c2c3[o]c(CO)nc3ccc2CC1)=O YIMZWSKKOJHNCV-UHFFFAOYSA-N 0.000 description 1
- FIPHYUVXAUQDEU-UHFFFAOYSA-N CCc1nc2ccc(CCC3CCNC(C)=O)c3c2[o]1 Chemical compound CCc1nc2ccc(CCC3CCNC(C)=O)c3c2[o]1 FIPHYUVXAUQDEU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a drug expected to be effective for the prevention or treatment of autism spectrum disorder containing a compound that can have melatonin receptor affinity.
- Autism spectrum disorder is a neurological development characterized by social disorders (eg, social communication disorder, interpersonal interaction disorder), limited repetitive style (eg, behavior, interest, activity, etc.) It is said to be one of the disorder groups (Non-Patent Document 1).
- social disorders eg, social communication disorder, interpersonal interaction disorder
- limited repetitive style eg, behavior, interest, activity, etc.
- Non-Patent Document 1 Non-Patent Document 1
- antipsychotic drugs are used for the purpose of preventing aggressive behaviors and self-injurious behaviors that are behavioral disorders associated with autism spectrum disorders, but they are symptomatic treatments and are not aimed at complete cure. Therefore, a therapeutic drug effective for an autism spectrum disorder (especially a drug effective for a social disorder) has been awaited in the medical field.
- Non-patent document 2 discloses that ramelteon was administered to two insomnia patients with autism to confirm the sleep disorder treatment effect of ramelteon, and items related to sleep disorder were evaluated. Yes.
- Patent Document 1 discloses the combined use of 5HTR agent and ramelteon and discloses autism as an application.
- Patent Document 2 discloses (S) -N- [2- (2-methyl-7,8-dihydro-6H-indeno [5,4-d] [1,3] oxazol-8-yl) ethyl] acetamide. Disclosure.
- Non-Patent Document 3 suggests that the amount of melatonin is decreased in patients with autism spectrum disorder, and that ASMT involved in melatonin synthesis in vivo is involved.
- Non-patent document 4 shows that the urinary melatonin metabolite (6-SM) in autistic patients decreases throughout the day, night, and day. Disclosed are results showing a negative correlation between the severity of autism and results showing a positive correlation between the amount of 6-SM in the urine and IQ score during the day.
- Non-Patent Document 5 suggests that melatonin has a therapeutic effect on sleep disorders in sleep disorders of children's insomnia patients with autism spectrum disorders and Fragile X syndrome.
- Non-Patent Document 6 reports that there are six studies in the past in which improvement of daytime behavior was reported in patients with autism spectrum disorder due to nighttime administration of melatonin.
- An object of the present invention is to provide a drug expected to be effective for the prevention or treatment of autism spectrum disorder, which contains a compound that can have melatonin receptor affinity.
- the present invention [1] N- [2- (2-Methyl-6,7-dihydro-8H-indeno [5,4-d] [1,3] oxazol-8-ylidene) ethyl] acetamide, N- [2- (2-Methyl-6H-indeno [5,4-d] [1,3] oxazol-8-yl) ethyl] acetamide, N- [2- (2-Methyl-6,7-dihydro-8H-indeno [5,4-d] [1,3] oxazol-8-ylidene) ethyl] propionamide, N- ⁇ 2- [2- (4-phenylbutyl) -6,7-dihydro-8H-indeno [5,4-d] [1,3] oxazol-8-ylidene) ethyl] propionamide, N- ⁇ 2- [2- (4-phenylbutyl) -6,7-dihydro
- a prophylactic or therapeutic agent for autism spectrum disorder comprising [3] For mammals, (N- [2- (2-Methyl-6,7-dihydro-8H-indeno [5,4-d] [1,3] oxazol-8-ylidene) ethyl] acetamide; N- [2- (2-Methyl-6H-indeno [5,4-d] [1,3] oxazol-8-yl) ethyl] acetamide, N- [2- (2-Methyl-6H-indeno [5,4-d] [1,3] oxazol-8-yl) ethyl] acetamide, N- [2- (2-Methyl-6,7-dihydro-8H-indeno [5,4-d] [1,3] oxazol-8-ylidene) ethyl] propionamide, N- ⁇ 2-
- a drug that contains a compound having melatonin receptor affinity as an active ingredient and is expected to be effective for the prevention and treatment of autism spectrum disorder.
- Examples of the salt of the compound of the present invention include pharmacologically acceptable salts.
- Examples include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
- Preferable examples of the salt with an inorganic base include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, aluminum salt and ammonium salt.
- Preferable examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N, N′-dibenzylethylenediamine.
- Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- salt with organic acid examples include formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, and benzenesulfone. And salts with acid, p-toluenesulfonic acid and the like.
- salts with basic amino acids include salts with arginine, lysine, ornithine and the like
- salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like. It is done. Among them, pharmaceutically acceptable salts are preferable.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be used.
- Salts with organic acids such as acetic acid, phthalic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid, etc., and having an acidic functional group
- Examples thereof include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, ammonium salt and the like.
- the compound of the present invention may be a hydrate or a non-hydrate.
- the compound of the present invention can be produced according to a method known per se, for example, the production method described in WO2007 / 148808 published on June 18, 2007 and published, or a method analogous thereto.
- the compound of the present invention may be a crystal, and the compound of the present invention includes a single crystal form or a mixture of crystal forms.
- the crystal can be produced by crystallization by applying a crystallization method known per se.
- the compound of the present invention or a salt thereof may be a pharmaceutically acceptable cocrystal or cocrystal salt.
- co-crystals or co-crystal salts are two or more unique at room temperature, each having different physical properties (eg structure, melting point, heat of fusion, hygroscopicity, solubility and stability). It means a crystalline substance composed of a simple solid.
- the cocrystal or cocrystal salt can be produced according to a cocrystallization method known per se.
- the compound of the present invention includes solvates (for example, hydrates) and non-solvates within the scope thereof.
- the compound of the present invention may be a compound labeled or substituted with an isotope (eg, 2 H, 3 H, 11 C, 14 C, 18 F, 35 S, 125 I, etc.).
- a compound labeled or substituted with an isotope can be used, for example, as a tracer (PET tracer) used in Positron Emission Tomography (PET), and can be useful in fields such as medical diagnosis.
- isomers such as enantiomers or diastereomers may exist. All such isomers and mixtures thereof are included within the scope of the present invention. Further, isomers due to conformation or tautomerism may be produced, and such isomers or mixtures thereof are also included in the compound of the present invention.
- the compound of the present invention generates a stereoisomer depending on the type of substituent, and the present invention includes both the isomer and a mixture thereof.
- the compound of the present invention may be used as a prodrug.
- a prodrug of the compound of the present invention is a compound that is converted into the compound of the present invention by a reaction with an enzyme, gastric acid or the like under physiological conditions in vivo, that is, enzymatically oxidizes, reduces, hydrolyzes, etc. and changes to the compound of the present invention.
- the compound of the present invention can be used for mammals (eg, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, humans, etc.) for autism spectrum disorders [eg, social disorders (eg, social disorders).
- Autism spectrum disorder with social communication disorder, interpersonal interaction disorder, etc. autism spectrum disorder with limited repetitive mode (eg, behavior, interest, activity, etc.), pervasive developmental disorder, autism (Eg, childhood autism, infant autism, high-functioning autism, childhood psychosis, Canner syndrome, atypical autism, etc.), Rett syndrome, Asperger syndrome (eg, autistic psychosis, Schizophrenia disorder, etc.)
- Childhood disintegration disorder eg, infantile dementia, disintegrating psychosis, Heller syndrome, symbiotic psychosis, etc.
- Down syndrome Kabuki syndrome, Vulnerable X syndrome, Cleef's Kleefstra syndrome, Rubinstein-Tybi syndrome, neurofibromatosis type 1 (NF1),
- the compound of the present invention can exhibit high affinity for melatonin receptors (MT1 receptor, MT2 receptor). Since the compound of the present invention can act as a melatonin agonist and can be useful as a melatonin receptor affinity composition, particularly a melatonin receptor agonist, it can be expected to have an excellent therapeutic effect on the above-mentioned diseases.
- R 1 represents an optionally substituted hydrocarbon group, an optionally substituted amino group, an optionally substituted hydroxy group or an optionally substituted heterocyclic ring. Indicates a group; R 5 has a hydrogen atom, a halogen atom, a hydrocarbon group which may have a substituent, an amino which may have a substituent, a hydroxy which may have a substituent, or a substituent.
- R 6 represents a hydrogen atom or a hydrocarbon group which may have a substituent
- X represents an oxygen atom or a sulfur atom
- m represents 0, 1 or 2
- Ring A represents an optionally substituted 5-membered ring
- Ring B represents a 6-membered ring which may have a substituent
- Ring C represents an optionally substituted 5-membered ring
- R 1 is an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 cycloalkyl, or an optionally substituted C 2-6 alkenyl.
- R 2 is a hydrogen atom, a hydrocarbon group which may have a substituent, or a heterocyclic group which may have a substituent
- R 3 is a hydrogen atom, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, or an optionally substituted amino
- Each of R 4a and R 4b is the same or different and is a hydrogen atom, a halogen atom, an optionally substituted hydroxy or an optionally substituted C 1-6 alkyl;
- R 1a is, (a) C 1-6 alkyl - carbonyloxy, hydroxy and 1-3 may have a substituent group C 1-6 alkyl selected from halogen atoms, (b) C 3-6 Cycloalkyl, (c) phenyl or (d) mono- or di-C 1-6 alkylamino;
- R 2a is a hydrogen atom or C 1-6 alkyl;
- R 2b is a hydrogen atom or hydroxy;
- R 3a has 1 to 3 substituents selected from (a) hydrogen atom, (b) phenyl, hydroxy, halogen atom, C 1-6 alkyl-carbonyl, C 7-13 aralkyloxy and pyridyl.
- drugs such as tasimelteon, agomelatin, melatonin sustained-release preparation, and pediatric melatonin sustained-release preparation may be useful for the prevention or treatment of autism spectrum disorder.
- the compound of the present invention can be expected to be excellent in solubility in water, the second solution of the Japanese Pharmacopoeia Dissolution Test, or the second solution of the Japanese Pharmacopoeia Disintegration Test, and the pharmacokinetics (eg, blood drug half-life, translocation into the brain) , Metabolic stability, CYP inhibition) and low toxicity (eg acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity, phototoxicity
- pharmacokinetics eg, blood drug half-life, translocation into the brain
- low toxicity eg acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity, phototoxicity
- mammals eg, mice, rats, hamsters, rabbits, cats, dogs.
- Parenteral includes intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, ophthalmic, intracerebral, intrarectal, intravaginal, intraperitoneal, intratumoral, proximal to tumor, etc. Includes direct lesion administration.
- the agent of the present invention may be in any form of solid preparations such as powders, granules, tablets, capsules, orally disintegrating films, and liquids such as syrups, emulsions and injections.
- the agent of the present invention can be produced by a conventional method such as mixing, kneading, granulation, tableting, coating, sterilization, emulsification, etc., depending on the form.
- a conventional method such as mixing, kneading, granulation, tableting, coating, sterilization, emulsification, etc.
- each item of a Japanese Pharmacopoeia formulation general rule etc. can be referred, for example.
- the agent of the present invention may be formed into a sustained release agent containing an active ingredient and a biodegradable polymer compound.
- the sustained-release agent can be prepared according to the method described in JP-A-9-263545.
- the content of the compound of the present invention varies depending on the form of the preparation, but usually 0.01 to 100% by weight, preferably as the amount of the compound of the present invention or a salt thereof relative to the whole preparation (whole drug) It is about 0.1 to 50% by weight, more preferably about 0.5 to 20% by weight.
- the compound of the present invention may be used as it is or in an appropriate pharmacologically acceptable carrier, for example, excipients (for example, starch, lactose, sucrose, calcium carbonate, calcium phosphate, etc.), binders (for example, starch, gum arabic, Carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, alginic acid, gelatin, polyvinylpyrrolidone, etc.), lubricant (eg, stearic acid, magnesium stearate, calcium stearate, talc, etc.), disintegrant (eg, carboxymethylcellulose calcium, talc, etc.) ), Diluents (for example, water for injection, physiological saline, etc.), and additives (for example, stabilizers, preservatives, colorants, fragrances, solubilizers, emulsifiers, buffers, tonicity agents, etc.) as necessary ) Etc.
- excipients for example, starch,
- powders, fine granules, granules Tablets may be administered orally or parenterally in the form of a solution, such as a solid, or injectable preparations such capsules.
- the compound of the present invention or a salt thereof can be directly administered to an affected part such as a joint disease when formed into a topical preparation and administered. In this case, an injection is preferable.
- a parenteral agent for local administration eg, injection into intramuscular, subcutaneous, organ, joint sites, solid preparations such as implants, granules, powders, liquids such as suspensions, ointments, etc.
- the compound of the present invention is used as a dispersant (eg, surfactants such as Tween 80, HCO-60, polysaccharides such as carboxymethylcellulose, sodium alginate, hyaluronic acid, polysorbate, etc.), preservatives ( Examples, methylparaben, propylparaben, etc.), isotonic agents (eg, sodium chloride, mannitol, sorbitol, glucose, etc.), buffers (eg, calcium carbonate, etc.), pH adjusters (eg, sodium phosphate, potassium phosphate)
- a dispersant eg, surfactants such as Tween 80, HCO-60, polysaccharides such as carboxymethylcellulose, sodium alginate, hyaluronic acid, polysorbate, etc.
- preservatives examples, methylparaben, propylparaben, etc.
- isotonic agents eg, sodium chloride, mannitol, sorbitol, glucose
- Injectables that can be used as oily suspensions by dispersing together with vegetable oils such as sesame oil and corn oil or those mixed with phospholipids such as lecithin or medium chain fatty acid triglycerides (eg, miglycol 812). It can be.
- vegetable oils such as sesame oil and corn oil or those mixed with phospholipids such as lecithin or medium chain fatty acid triglycerides (eg, miglycol 812). It can be.
- the dose of the compound of the present invention varies depending on the administration subject, administration route, target disease, symptom, etc.
- it is usually about 0.01 to 100 mg / kg body weight as a single dose, preferably It is 0.1-50 mg / kg body weight, more preferably 0.5-20 mg / kg body weight, and this amount can be administered once to three times a day.
- the agent of the present invention can be obtained by using the compound of the present invention alone or in combination with a pharmacologically acceptable carrier according to a method known per se as a method for producing a pharmaceutical preparation (eg, a method described in the Japanese Pharmacopoeia). Can be used as a mixed pharmaceutical composition.
- a method for producing a pharmaceutical preparation eg, a method described in the Japanese Pharmacopoeia
- examples of the agent of the present invention include tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules and microcapsules).
- Lozenges syrups, solutions, emulsions, suspensions, controlled-release preparations (eg, immediate-release preparations, sustained-release preparations, sustained-release microcapsules), aerosols, films (eg, oral) Disintegrating film, oral mucosa adhesive film), injection (eg, subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection), instillation, transdermal preparation, ointment, lotion, patch Pharmaceutical compositions such as suppositories, suppositories (eg, rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), eye drops, etc., orally or parenterally (eg, intravenously) Intramuscular, subcutaneous, intraorgan, intranasal, intradermal, ophthalmic, intracerebral, direct Among them, intravaginally, intraperitoneally, be safely administered into a lesion, etc.).
- various organic or inorganic carriers conventionally used as starting materials can be used.
- excipients lubricants, binders and disintegrants
- liquid preparations solvents, solubilizers, suspending agents, isotonic agents, buffering agents, And soothing agents may be used.
- formulation additives such as preservatives, antioxidants, coloring agents, sweeteners and the like can be used.
- excipients examples include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, and light anhydrous silicic acid.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, and the like.
- disintegrant examples include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl starch sodium, L-hydroxypropyl cellulose, and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
- solubilizer examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol, polyvinylpyrrolidone And hydrophilic polymers such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and the like.
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate
- polyvinyl alcohol polyvinylpyrrolidone
- hydrophilic polymers such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose
- isotonic agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- buffer solutions such as phosphate, acetate, carbonate, citrate, and the like.
- Examples of soothing agents include benzyl alcohol.
- preservative examples include p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- the pharmaceutical composition varies depending on the dosage form, administration method, carrier and the like, but the compound of the present invention is usually 0.01 to 100% (w / w), preferably 0.1 to 95% (w / w) based on the total amount of the preparation. It can manufacture in accordance with a conventional method by adding in the ratio of w).
- the compound of the present invention can be expected to have extremely low toxicity, and can be used for the prevention or treatment of autism spectrum disorder in combination with other drugs, and the excellent preventive / therapeutic effect of such combined use with other drugs Can be expected.
- combination therapy can be expected to reduce the side effects of other autism spectrum disorders by lowering the dose of a prophylactic or therapeutic agent.
- Examples of a drug that can be used in combination with the compound of the present invention include, for example, “an other prophylactic or therapeutic agent for autism spectrum disorder” (eg, serotonin / dopamine antagonist ( Risperidone, olanzapine, quetiapine, clozapine, ziprasidone, and the like) and dopamine partial agonists (such as aripiprazole).
- an other prophylactic or therapeutic agent for autism spectrum disorder eg, serotonin / dopamine antagonist ( Risperidone, olanzapine, quetiapine, clozapine, ziprasidone, and the like
- dopamine partial agonists such as aripiprazole
- the compound of the present invention can be used in combination with non-drug therapy.
- non-drug therapy (1) surgery; (2) pressor chemotherapy using angiotensin II or the like; (3) gene therapy; (4) hyperthermia; (5) cryotherapy; (6) (7) Radiotherapy; (8) Immunotherapy; (9) Regenerative medicine; (10) Cell therapy; (11) Psychotherapy or psychosocial therapy.
- These concomitant drugs may be free forms or pharmaceutically acceptable salts.
- such salts include alkali metal salts (eg, sodium salts, potassium salts, etc.), alkaline earth metal salts (eg, calcium salts, magnesium salts, barium salts, etc.) when the drug has an acidic functional group.
- Inorganic salts such as ammonium salts, etc.
- the drug when the drug has a basic functional group, for example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, or acetic acid, phthalates
- salts with organic acids such as acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, and p-toluenesulfonic acid.
- the concomitant drug illustrated here can be easily obtained as a commercial product, or can be produced according to a known method.
- the administration form for example, (1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and a concomitant drug, (2) Simultaneous administration by the same route of administration of two types of preparations obtained by separately formulating the compound of the present invention and a concomitant drug, (3) Administration of the two compounds obtained by separately formulating the compound of the present invention and the concomitant drug with a time difference in the same administration route, (4) Simultaneous administration by different administration routes of two types of preparations obtained by separately formulating the compound of the present invention and a concomitant drug, (5) Administration of the two preparations obtained by separately formulating the compound of the present invention and the concomitant drug at different time intervals in different administration routes (for example, administration in the order of the compound of the present invention ⁇ the concomitant drug, or Administration in reverse order) Etc. From the viewpoint of patient convenience, administration of a single preparation obtained by simultaneously formulating the compound of the present invention and a concomitant drug, (2) Simultane
- the dose of the concomitant drug can be appropriately selected based on the clinically used dose.
- the compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, symptom, type of concomitant drug used, and the like. Usually, it can be determined on the basis of the general dose of the concomitant drug used.
- the administration subject is a human, for example, 0.01 to 100 parts by weight of the concomitant drug can be used per 1 part by weight of the compound of the present invention.
- the concomitant agent in the present invention can be used as a pharmaceutical composition obtained by mixing the compound of the present invention or (and) the above concomitant drug with a pharmacologically acceptable carrier.
- the compounding ratio of the compound of the present invention and the concomitant drug in the concomitant drug of the present invention can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination and the like.
- the content of the compound of the present invention in the concomitant drug in the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0.1 to 50% by weight, based on the whole preparation, More preferably, it is about 0.5 to 20% by weight.
- the content of the concomitant drug in the concomitant drug in the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0.1 to 50% by weight, more preferably about the whole preparation. About 0.5 to 20% by weight.
- the content of additives such as carriers in the concomitant drug in the present invention varies depending on the form of the preparation, but is usually about 1 to 99.99% by weight, preferably about 10 to 90% by weight, based on the whole preparation. .
- the same content may be used when the compound of the present invention and the concomitant drug are formulated separately.
- the compounds of the following production examples can be produced according to a method known per se, for example, the reference examples and examples described in WO 2007/148808 filed and published on June 18, 2007, or a method analogous thereto. .
- Example 1 The effect of the compound of the present invention on the social disorder in the rat valproate-exposed autism model was used in the rat embryonic valproate-exposed autism model.
- Sprague-Dawley pregnant rats were intraperitoneally administered with sodium valproate (VPA) 500 mg / kg (mpk) on embryonic day 12.5.
- the litters were weaned 21 days after birth, and only male rats were used for the experiment.
- Compound A (0.2 or 1 mg / kg) was orally administered once a day at 18:00 from 3 weeks after weaning for 14 days, and a behavioral test was conducted at 5 weeks of age.
- Stranger rats were male rats purchased from the same strain and the same age, so that there was no contact with the test rats until the test date.
- a black plastic three-chamber experimental apparatus (90 ⁇ 60 ⁇ 34 cm, each chamber 30 ⁇ 60 ⁇ 34 cm) was used.
- Each chamber partition was made of transparent plastic, with a 10 x 12 cm opening at the bottom, allowing the rat to move freely between the compartments through this opening.
- the left and right compartments in the experimental apparatus have clear acrylic cylinders (12 cm in diameter, 25 cm in height, 1.5 cm in diameter on the side, with black hemispherical metal lids) 1 each Individuals were set up to prevent direct contact with strange rats. On the day of the test, the test and unknown rats were acclimated to the test environment for at least 1 hour before starting the test.
- the three-chamber apparatus placed a transparent partition plate without an opening so that it could not enter the left and right compartments, and the test rat was placed in the central compartment for 5 minutes. After 5 minutes, place an unknown rat in one cylinder, an object (white sphere) in the other cylinder, gently remove the transparent partition without openings, and the test rat can freely move to the left and right compartments. I made it possible.
- the sniffing (sniffing object and animal) time for each cylinder was visually measured for 10 minutes.
- a sniffing index which is an index indicating interest in another animal, was calculated using the following formula based on the sniffing time for each cylinder for 10 minutes. The results are shown in FIG.
- Formulation Example 1 After uniformly mixing 160 g of Compound A, 4064 g of lactose, and 640 g of corn starch in a fluidized bed granulator / dryer, an aqueous solution in which 160 g of hydroxypropylcellulose is dissolved is sprayed and granulated in the machine, and then dried in the same machine. The obtained granulated product is crushed with a 1.5 mm ⁇ punching screen using a power mill to obtain a sized powder. 3894 g of this sized powder is taken, 124 g of corn starch and 12.4 g of magnesium stearate are added thereto, and mixed to obtain granules for tableting.
- This granule is compressed to a weight of 130 mg with a tableting machine using a 7.0 mm ⁇ punch to form an uncoated tablet.
- the obtained uncoated tablet was sprayed with hydroxypropylmethylcellulose 2910 in which titanium oxide and yellow ferric oxide were dispersed in a film coating machine and a copolyvidone solution, and the film tablet having the formulation shown in Table 1 containing 4 mg of compound A per tablet, About 25000 tablets are obtained.
- a drug that contains a compound having melatonin receptor affinity as an active ingredient and is expected to be effective for the prevention and treatment of autism spectrum disorder.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
自閉症スペクトラム障害は社会性障害(例、社会的コミュニケーション障害、対人相互反応障害など)、限定された反復的な様式(例、行動、興味、活動など)等を症状の特徴とする神経発達障害群の一つと言われている(非特許文献1)。現在はまだ治療方法は確立されていないが、薬剤の処方によって生活の改善を図っている。例えば、自閉症スペクトラム障害に伴う行動障害である攻撃的行動や自傷行動を防ごうという理由で、抗精神病薬が用いられるが、対症療法であり根治を目指すものではない。
従って、自閉症スペクトラム障害に有効な治療薬(特に、社会性障害に有効な薬剤)が医療の現場では待たれていた。
非特許文献2は、自閉症を伴う不眠症患者2名に、ラメルテオン(ramelteon)の睡眠障害治療効果を確認するためラメルテオンを投与したことを開示し、睡眠障害に関連した項目について評価している。
特許文献1は、5HTR剤等とラメルテオンの併用を開示し、適用用途として、自閉症を開示している。
特許文献2は、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドを開示している。
非特許文献3は、自閉症スペクトラム障害患者でメラトニンの量が減少しており、生体内のメラトニン合成に関与するASMTが関与することを示唆している。
非特許文献4は、自閉症患者の尿中のメラトニン代謝物(6-SM)が日中、夜間、一日を通じて減少している結果、夜間の尿中6-SM量と言語能力等の自閉症の重篤度が負の相関を示す結果、および日中の尿中6-SM量とIQスコア等が正の相関を示す結果を開示している。
非特許文献5は、自閉症スペクトラム障害及び脆弱性X(Fragile X)症候群を伴う子供の不眠症患者の睡眠障害で、メラトニンが睡眠障害に治療効果を有することを示唆している。
非特許文献6は、メラトニンの夜間投与により自閉症スペクトラム障害患者において、日中行動の改善が報告された試験が過去に6つあること等を報告している。
すなわち、本発明は、
[1]N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩(本明細書中、「本発明化合物」と略記する場合がある)を有効成分として含有する、自閉症スペクトラム障害の予防または治療剤(本明細書中、「本発明の剤」と略記する場合がある);
[2](S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩を有効成分として含有する、自閉症スペクトラム障害の予防または治療剤;
[3]哺乳動物に対して、
(N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩を有効量投与することを特徴とする、自閉症スペクトラム障害の予防または治療方法;
[4]哺乳動物に対して、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩を有効量投与することを特徴とする、自閉症スペクトラム障害の予防または治療方法;
[5]自閉症スペクトラム障害の予防または治療剤として使用するための、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩;
[6]自閉症スペクトラム障害の予防または治療における使用のための、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩;
[7]自閉症スペクトラム障害の予防または治療剤を製造するための、
(N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩の使用;
[8]自閉症スペクトラム障害の予防または治療薬を製造するための、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩の使用;
などに関する。
本発明化合物のなかでも、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドが好ましい。
中でも薬学的に許容可能な塩が好ましく、その例としては、本発明化合物内に塩基性官能基を有する場合には、例えば塩酸、臭化水素酸、硝酸、硫酸、リン酸などの無機酸との塩、例えば酢酸、フタル酸、フマル酸、酒石酸、マレイン酸、クエン酸、コハク酸、メタンスルホン酸、p-トルエンスルホン酸などの有機酸との塩があげられ、酸性官能基を有する場合には、例えばナトリウム塩、カリウム塩などのアルカリ金属塩、カルシウム塩、マグネシウム塩などのアルカリ土類金属塩、アンモニウム塩などがあげられる。
また、本発明化合物は、水和物であっても、非水和物であってもよい。
本発明化合物またはその塩は、薬学的に許容され得る共結晶または共結晶塩であってもよい。ここで、共結晶または共結晶塩とは、各々が異なる物理的特性(例えば、構造、融点、融解熱、吸湿性、溶解性および安定性等)を持つ、室温で二種またはそれ以上の独特な固体から構成される結晶性物質を意味する。共結晶または共結晶塩は、自体公知の共結晶化法に従い製造することができる。
本発明化合物は、溶媒和物(例えば、水和物)および無溶媒和物をその範囲内に包含する。なお、本発明化合物は、同位元素(例、2H、3H、11C、14C、18F、35S、125Iなど)などで標識または置換された化合物であってもよい。同位元素で標識または置換された化合物は、例えば、陽電子断層法(Positron Emission Tomography,PET)において使用するトレーサー(PETトレーサー)として用い得、医療診断などの分野において有用であり得る。
さらに、WO2007/148808に記載の式
R1は、置換基を有していてもよい炭化水素基、置換基を有していてもよいアミノ、置換基を有していてもよいヒドロキシまたは置換基を有していてもよい複素環基を示し;
R5は、水素原子、ハロゲン原子、置換基を有していてもよい炭化水素基、置換基を有していてもよいアミノ、置換基を有していてもよいヒドロキシまたは置換基を有していてもよいメルカプトを示し;
R6は、水素原子または置換基を有していてもよい炭化水素基を示し;
Xは、酸素原子または硫黄原子を示し;
mは0、1または2を示し;
環Aは置換基を有していてもよい5員環を示し;
環Bは置換基を有していてもよい6員環を示し;
環Cは置換基を有していてもよい5員環を示し;
化合物(I)のなかでも、式
R1が、置換基を有していてもよいC1-6アルキル、置換基を有していてもよいC3-6シクロアルキルまたは置換基を有していてもよいC2-6アルケニルであり;
R2が、水素原子、置換基を有していてもよい炭化水素基または置換基を有していてもよい複素環基であり;
R3が、水素原子、置換基を有していてもよいC1-6アルキル、置換基を有していてもよいC2-6アルケニルまたは置換基を有していてもよいアミノであり;
R4aおよびR4bが、それぞれ同一または異なって、水素原子、ハロゲン原子、置換基を有していてもよいヒドロキシまたは置換基を有していてもよいC1-6アルキルであり;
R5が、水素原子または置換基を有していてもよいC1-6アルキルであり;および
R6が、水素原子または置換基を有していてもよいC1-6アルキルである化合物またはその塩が好ましい。
化合物(I)のなかでも、特に式
R1aが、(a)C1-6アルキル-カルボニルオキシ、ヒドロキシおよびハロゲン原子から選ばれる1~3個の置換基を有していてもよいC1-6アルキル、(b)C3-6シクロアルキル、(c)フェニルまたは(d)モノ-もしくはジ-C1-6アルキルアミノであり;
R2aが水素原子またはC1-6アルキルであり;
R2bが水素原子またはヒドロキシであり;
R3aが、(a)水素原子、(b)フェニル、ヒドロキシ、ハロゲン原子、C1-6アルキル-カルボニル、C7-13アラルキルオキシおよびピリジルから選ばれる1~3個の置換基を有していてもよいC1-6アルキル、(c)C3-6シクロアルキル、(d)フェニル、(e)C1-6アルコキシ、(f)メルカプト、(g)C1-6アルキルチオまたは(h)モノ-もしくはジ-C1-6アルキルアミノである。〕
で表される化合物またはその塩が好ましい。
前記式中、
このような本発明化合物と組み合わせて用いられ得る薬剤(以下、併用薬剤と略記する)としては、例えば、「他の自閉症スペクトラム障害の予防または治療剤」(例、セロトニン・ドパミン拮抗薬(リスペリドン、オランザピン、クエチアピン、クロザピン、ジプラシドンなど)、ドパミン部分作動薬(アリピプラゾールなど)など)が挙げられる。
以下、本発明化合物と併用薬剤を併用して使用することを「本発明における併用剤」と称する。
本発明化合物が併用薬剤と組み合せて使用される場合には、お互いの剤の量は、それらの剤の反対効果を考えて安全な範囲内で低減し得る。したがって、これらの剤により引き起こされるであろう反対効果は安全に防止し得る。
本発明化合物は、非薬剤療法と併用し得る。ここで、非薬剤療法の具体例としては、(1)手術;(2)アンジオテンシンII等を用いる昇圧化学療法;(3)遺伝子療法;(4)温熱療法;(5)凍結療法;(6)レーザー焼灼法;(7)放射線療法;(8)免疫療法;(9)再生医療法;(10)細胞治療法;(11)精神療法または心理社会的療法が挙げられる。
(1)本発明化合物と併用薬剤とを同時に製剤化して得られる単一の製剤の投与、
(2)本発明化合物と併用薬剤とを別々に製剤化して得られる2種の製剤の同一投与経路での同時投与、
(3)本発明化合物と併用薬剤とを別々に製剤化して得られる2種の製剤の同一投与経路での時間差をおいての投与、
(4)本発明化合物と併用薬剤とを別々に製剤化して得られる2種の製剤の異なる投与経路での同時投与、
(5)本発明化合物と併用薬剤とを別々に製剤化して得られる2種の製剤の異なる投与経路での時間差をおいての投与(例えば、本発明化合物→併用薬剤の順序での投与、あるいは逆の順序での投与)、
などが挙げられる。
患者の利便性の観点からは、本発明化合物と併用薬剤とを同時に製剤化して得られる単一の製剤の投与が、特に好ましい態様と言える。
例えば、本発明における併用剤における本発明化合物の含有量は、製剤の形態によって相違するが、通常製剤全体に対して約0.01~100重量%、好ましくは約0.1~50重量%、さらに好ましくは約0.5~20重量%程度である。
N-[2-(6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド
N-[2-(6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}プロピオンアミド
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド
N-[2-(7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド
N-{2-[2-(4-フェニルブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(4-フェニルブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}プロピオンアミド
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-{2-[2-(ヒドロキシメチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-[2-(2-イソプロピル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-{2-[2-(トリフルオロメチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(4-ヒドロキシブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(3-ヒドロキシブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(3-オキソブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-[2-(2-シクロプロピル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(2-フェニル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(2-ベンジル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-{2-[2-(2-フェニルエチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(3-フェニルプロピル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-(2-{2-[(ベンジルオキシ)メチル]-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル}エチル)アセトアミド
N-(2-{2-[4-(ベンジルオキシ)ブチル]-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル}エチル)アセトアミド
N-(2-{2-[3-(ベンジルオキシ)ブチル]-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル}エチル)アセトアミド
N-{2-[2-(4-ピリジン-2-イルブチル)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-{2-[2-(メチルチオ)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
N-{2-[2-(ジメチルアミノ)-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル]エチル}アセトアミド
1-メチル-2-{[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アミノ}-2-オキソエチル アセタート
2-ヒドロキシ-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロパンアミド
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]シクロプロパンカルボキサミド
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]ベンズアミド
2,2,2-トリフルオロ-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
1-エチル-3-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]尿素
N-[2-(2-メルカプト-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(8-ヒドロキシ-7-イソプロピル-2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
N-[2-(7-イソプロピル-2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
ラットバルプロ酸暴露自閉症モデルの社会性障害に対する本発明化合物の効果
試験には、ラット胎生期バルプロ酸暴露自閉症モデルを使用した。Sprague-Dawley系妊娠ラットの胎生期12.5日目にバルプロ酸ナトリウム(VPA)500 mg/kg(mpk)を腹腔内投与した。産仔は生後21日に離乳し、雄性ラットのみ実験に使用した。離乳後の3週齢から1日1回18時に化合物A(0.2または1 mg/kg) を14日間経口投与し、5週齢で行動試験を行った。見知らぬラット(Stranger rat)は、同系統、同週齢の購入した雄性ラットを使用し、被験ラット(test rat)と試験日までコンタクトが一切ないようにした。
実験には、黒色プラスチック製3チャンバー実験装置(90×60×34 cm、各チャンバー30×60×34 cm) を使用した。各チャンバーの仕切りは、透明プラスチック製で、下部には10×12 cm の開口部を作り、この開口部を通ってラットが各コンパートメント間を自由に行き来できるようにした。実験装置内の左右のコンパートメントには、透明アクリル製のシリンダー (直径12 cm、高さ25 cm、側面に直径1.5 cmの穴が等間隔で開いている、黒色半球状金属製蓋付) 各1個を設置し、直接見知らぬラットとコンタクト出来ないようにした。
試験当日、被験ラットおよび見知らぬラットは試験環境へ1時間以上馴化後、試験を開始した。3チャンバー装置は左右のコンパートメントに進入できないよう開口部のない透明仕切り板を置き、中央のコンパートメントに被験ラットを5分間入れた。5分経過後、一方のシリンダーに見知らぬラット、もう一方のシリンダーに物体(object) (白球体) を入れ、開口部のない透明仕切り板を静かに外し、被験ラットが左右のコンパートメントに自由に行き来出来るようにした。目視により各シリンダーへのスニッフィング(sniffing)(物体や動物を嗅ぐ行動)時間を10分間計測した。別な動物に対する興味を示す指標であるスニッフィングインデックス(Sniffing index)は、10分間の各シリンダーへのスニッフィング時間を基に下記に示した式を用いて算出した。結果を図1に示す。
スニッフィングインデックス = ((見知らぬラットの入ったシリンダーへのスニッフィング時間 (sec)) - (物体の入ったシリンダーへのスニッフィング時間 (sec))) / ((見知らぬラットの入ったシリンダーへのスニッフィング時間 (sec)) + (物体の入ったシリンダーへのスニッフィング時間 (sec)))
社会性行動(Sociability)試験において、胎生期バルプロ酸暴露ラットはコントロールに比して別な動物に対する興味を示す指標であるスニッフィングインデックスの有意 (***P < 0.001) な低下、および物体 (無生物) を入れたシリンダーへのスニッフィング時間の有意 (**P < 0.01) な増加を示し、社会性障害が認められた。それらに対して、化合物A (0.2または1 mg/kg) の慢性投与は、有意 (#P < 0.025) な社会性の改善効果を示した。
化合物Aの慢性投与はラット胎生期バルプロ酸暴露自閉症モデルの社会性障害に対して有効性を示した。
流動層造粒乾燥機中で化合物A 160g、乳糖4064g、およびトウモロコシデンプン640gを均一に混合後、機内でヒドロキシプロピルセルロース160gを溶解した水溶液を噴霧して造粒し、ついで同機で乾燥する。得られた造粒物をパワーミルを用い、1.5mmφパンチングスクリーンで解砕して整粒末とする。この整粒末を3894gとり、これにトウモロコシデンプン124gとステアリン酸マグネシウム12.4gを加え、混合して打錠用顆粒とする。この顆粒を打錠機で7.0mmφの杵を用いて重量130mgに打錠し素錠とする。得られた素錠はフィルムコーティング機中で酸化チタン、黄色三二酸化鉄を分散したヒドロキシプロピルメチルセルロース2910、コポリビドン溶液を噴霧し、1錠当たり化合物Aを4mg含有する表1に示す処方のフィルム錠、約25000錠を得る。
Claims (8)
- N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩を有効成分として含有する、自閉症スペクトラム障害の予防または治療剤。 - (S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩を有効成分として含有する、自閉症スペクトラム障害の予防または治療剤。
- 哺乳動物に対して、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩を有効量投与することを特徴とする、自閉症スペクトラム障害の予防または治療方法。 - 哺乳動物に対して、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩を有効量投与することを特徴とする、自閉症スペクトラム障害の予防または治療方法。
- 自閉症スペクトラム障害の予防または治療における使用のための、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩。 - 自閉症スペクトラム障害の予防または治療における使用のための、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩。
- 自閉症スペクトラム障害の予防または治療薬を製造するための、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン)エチル]プロピオンアミド、
N-{2-[2-(4-フェニルブチル)-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]オキサゾール-8-イリデン]エチル}アセトアミド、
N-[2-(2-メチル-6,7-ジヒドロ-8H-インデノ[5,4-d][1,3]チアゾール-8-イリデン)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]プロピオンアミド、
N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]チアゾール-8-イル)エチル]アセトアミド、
N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(S)-N-[2-(2-エチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、
(R)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド、および
(S)-N-[2-(2-メトキシ-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミド
から選ばれる化合物またはその塩の使用。 - 自閉症スペクトラム障害の予防または治療薬を製造するための、(S)-N-[2-(2-メチル-7,8-ジヒドロ-6H-インデノ[5,4-d][1,3]オキサゾール-8-イル)エチル]アセトアミドまたはその塩の使用。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017205722A AU2017205722B2 (en) | 2016-01-08 | 2017-01-05 | Prophylactic or therapeutic agent for autism spectrum disorder |
KR1020187022719A KR20180100646A (ko) | 2016-01-08 | 2017-01-05 | 자폐 스펙트럼 장애의 예방 또는 치료제 |
ES17735992T ES2909904T3 (es) | 2016-01-08 | 2017-01-05 | Agente profiláctico o terapéutico para el trastorno del espectro autista |
JP2017560410A JP6893476B2 (ja) | 2016-01-08 | 2017-01-05 | 自閉症スペクトラム障害の予防または治療剤 |
US16/068,553 US10759768B2 (en) | 2016-01-08 | 2017-01-05 | Prophylactic or therapeutic agent for autism spectrum disorder |
CA3010804A CA3010804A1 (en) | 2016-01-08 | 2017-01-05 | Prophylactic or therapeutic agent for autism spectrum disorder |
CN201780014690.8A CN108697689B (zh) | 2016-01-08 | 2017-01-05 | 自闭症谱系障碍的预防或治疗剂 |
EP17735992.4A EP3400939B1 (en) | 2016-01-08 | 2017-01-05 | Prophylactic or therapeutic agent for autism spectrum disorder |
US16/935,531 US20210130305A1 (en) | 2016-01-08 | 2020-07-22 | Prophylactic or therapeutic agent for autism spectrum disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276354P | 2016-01-08 | 2016-01-08 | |
US62/276,354 | 2016-01-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/068,553 A-371-Of-International US10759768B2 (en) | 2016-01-08 | 2017-01-05 | Prophylactic or therapeutic agent for autism spectrum disorder |
US16/935,531 Division US20210130305A1 (en) | 2016-01-08 | 2020-07-22 | Prophylactic or therapeutic agent for autism spectrum disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017119455A1 true WO2017119455A1 (ja) | 2017-07-13 |
Family
ID=59274141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/000166 WO2017119455A1 (ja) | 2016-01-08 | 2017-01-05 | 自閉症スペクトラム障害の予防または治療剤 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10759768B2 (ja) |
EP (1) | EP3400939B1 (ja) |
JP (2) | JP6893476B2 (ja) |
KR (1) | KR20180100646A (ja) |
CN (1) | CN108697689B (ja) |
AU (1) | AU2017205722B2 (ja) |
CA (1) | CA3010804A1 (ja) |
ES (1) | ES2909904T3 (ja) |
WO (1) | WO2017119455A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180100646A (ko) * | 2016-01-08 | 2018-09-11 | 다케다 야쿠힌 고교 가부시키가이샤 | 자폐 스펙트럼 장애의 예방 또는 치료제 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008466A1 (en) | 1994-09-12 | 1996-03-21 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds, their production and use |
WO1997001539A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists |
WO1997005098A1 (en) | 1995-07-26 | 1997-02-13 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds with melatonine receptor binding affinity, their production and use |
WO1997032871A1 (en) | 1996-03-08 | 1997-09-12 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
JPH09263545A (ja) | 1995-06-05 | 1997-10-07 | Takeda Chem Ind Ltd | 骨形成促進医薬組成物 |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
WO2007148808A1 (en) | 2006-06-19 | 2007-12-27 | Takeda Pharmaceutical Company Limited | Tricyclic compound and pharmaceutical use thereof |
WO2008069311A1 (ja) | 2006-12-08 | 2008-06-12 | Takeda Pharmaceutical Company Limited | 三環性化合物およびその医薬用途 |
WO2008084717A1 (ja) | 2006-12-28 | 2008-07-17 | Takeda Pharmaceutical Company Limited | 三環性化合物およびその医薬用途 |
WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910492A (en) | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
KR20180100646A (ko) * | 2016-01-08 | 2018-09-11 | 다케다 야쿠힌 고교 가부시키가이샤 | 자폐 스펙트럼 장애의 예방 또는 치료제 |
WO2017119456A1 (ja) * | 2016-01-08 | 2017-07-13 | 武田薬品工業株式会社 | せん妄の予防または治療剤 |
-
2017
- 2017-01-05 KR KR1020187022719A patent/KR20180100646A/ko not_active Application Discontinuation
- 2017-01-05 CN CN201780014690.8A patent/CN108697689B/zh active Active
- 2017-01-05 WO PCT/JP2017/000166 patent/WO2017119455A1/ja active Application Filing
- 2017-01-05 CA CA3010804A patent/CA3010804A1/en active Pending
- 2017-01-05 AU AU2017205722A patent/AU2017205722B2/en active Active
- 2017-01-05 JP JP2017560410A patent/JP6893476B2/ja active Active
- 2017-01-05 EP EP17735992.4A patent/EP3400939B1/en active Active
- 2017-01-05 US US16/068,553 patent/US10759768B2/en active Active
- 2017-01-05 ES ES17735992T patent/ES2909904T3/es active Active
-
2020
- 2020-07-22 US US16/935,531 patent/US20210130305A1/en not_active Abandoned
-
2021
- 2021-04-16 JP JP2021069768A patent/JP7167235B2/ja active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008466A1 (en) | 1994-09-12 | 1996-03-21 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds, their production and use |
JPH09263545A (ja) | 1995-06-05 | 1997-10-07 | Takeda Chem Ind Ltd | 骨形成促進医薬組成物 |
WO1997001539A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists |
WO1997005098A1 (en) | 1995-07-26 | 1997-02-13 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds with melatonine receptor binding affinity, their production and use |
WO1997032871A1 (en) | 1996-03-08 | 1997-09-12 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
WO2007148808A1 (en) | 2006-06-19 | 2007-12-27 | Takeda Pharmaceutical Company Limited | Tricyclic compound and pharmaceutical use thereof |
JP2009541202A (ja) * | 2006-06-19 | 2009-11-26 | 武田薬品工業株式会社 | 三環性化合物およびその医薬用途 |
WO2008069311A1 (ja) | 2006-12-08 | 2008-06-12 | Takeda Pharmaceutical Company Limited | 三環性化合物およびその医薬用途 |
WO2008084717A1 (ja) | 2006-12-28 | 2008-07-17 | Takeda Pharmaceutical Company Limited | 三環性化合物およびその医薬用途 |
WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
Non-Patent Citations (10)
Title |
---|
"Diagnostic and Statistical Manual of Psychiatricc disorders, 5th Edition", pages: 50 - 59 |
KUMAR, H. ET AL.: "Benefits of agomelatine in behavioral, neurochemical and blood brain barrier alterations in prenatal valproic acid induced autism spectrum disorder", NEUROCHEMISTRY INTERNATIONAL, vol. 91, December 2015 (2015-12-01), pages 34 - 45, XP029312481, ISSN: 0197-0186, Retrieved from the Internet <URL:doi:10.1016/j.neuint.2015.10.007> * |
MELKE J: "Abnormal melatonin synthesis in autism spectrum disorders.", MOL PSYCHIATRY., vol. 13, no. 1, January 2008 (2008-01-01), pages 90 - 8 |
ROSSIGNOL DA: "Melatonin in autism spectrum disorders: a systematic review and meta-analysis", DEV MED CHILD NEUROL., vol. 53, no. 9, September 2011 (2011-09-01), pages 783 - 92 |
ROSSINGNOL, D.A. ET AL.: "Melatonin in autism spectrum disorders: a systematic review and meta-analysis", DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, vol. 53, no. 9, September 2011 (2011-09-01), pages 783 - 792, XP055508220, ISSN: 1469-8749, Retrieved from the Internet <URL:doi:10.1111/j.1469-8749.2011.03980.x> * |
See also references of EP3400939A4 |
STIGLER K. A., J CHILD ADOLESC PSYCHOPHARMACOL., vol. 16, no. 5, October 2006 (2006-10-01), pages 631 - 6 |
TORDJMAN S: "Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder", PSYCHONEUROENDOCRINOLOGY, vol. 37, no. 12, December 2012 (2012-12-01), pages 1990 - 7 |
TORDJMAN, S. ET AL.: "Advances in the Research of Melatonin in Autism Spectrum Disorders: Literature Review and New Perspectives", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 14, no. 10, 14 October 2013 (2013-10-14), pages 20508 - 20542, XP055508212, ISSN: 1422-0067, Retrieved from the Internet <URL:doi:10.3390/ijms141020508> * |
WIROJANAN J: "The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome", J CLIN SLEEP MED., vol. 5, no. 2, 15 April 2009 (2009-04-15), pages 145 - 50 |
Also Published As
Publication number | Publication date |
---|---|
US10759768B2 (en) | 2020-09-01 |
US20190040022A1 (en) | 2019-02-07 |
US20210130305A1 (en) | 2021-05-06 |
CN108697689A (zh) | 2018-10-23 |
EP3400939A1 (en) | 2018-11-14 |
JP7167235B2 (ja) | 2022-11-08 |
EP3400939A4 (en) | 2019-09-04 |
CA3010804A1 (en) | 2017-07-13 |
CN108697689B (zh) | 2022-04-26 |
JPWO2017119455A1 (ja) | 2018-10-25 |
KR20180100646A (ko) | 2018-09-11 |
EP3400939B1 (en) | 2022-03-16 |
JP2021107434A (ja) | 2021-07-29 |
ES2909904T3 (es) | 2022-05-10 |
JP6893476B2 (ja) | 2021-06-23 |
AU2017205722B2 (en) | 2022-02-17 |
AU2017205722A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
CA2641917A1 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
US11427540B2 (en) | Formulations of T-type calcium channel modulators and methods of use thereof | |
US20220096444A1 (en) | Prophylactic or therapeutic agent for delirium | |
TW201737943A (zh) | 使用fasn抑制劑之方法 | |
KR20070085973A (ko) | 수면 장애 예방 또는 치료제 | |
JP7167235B2 (ja) | 自閉症スペクトラム障害の予防または治療剤 | |
JPH11501051A (ja) | 強迫性障害、睡眠時無呼吸、性的機能障害、嘔吐および乗物酔いの処置を意図する医薬 | |
AU5287499A (en) | Use of (S)(-)-amisulpride for the manufacture of a medicament for the treatment of positive, negative, affective or cognitive symptoms of Schizophrenia | |
CN110200978A (zh) | 甲状腺β-激动剂的应用 | |
CN103097380A (zh) | 酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂 | |
KR20210005647A (ko) | 혈액뇌장벽을 통한 전달을 위한 아세틸화된 프로드러그 | |
US20080033045A1 (en) | Treatment of psychiatric disorders | |
BR112017027839B1 (pt) | Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento | |
JP2014201578A (ja) | 線維筋痛症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17735992 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017560410 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3010804 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017205722 Country of ref document: AU Date of ref document: 20170105 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187022719 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020187022719 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017735992 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017735992 Country of ref document: EP Effective date: 20180808 |